Search for a trial

The effects of the proton pump inhibitor esomeprazole on the bioavailability of regorafenib in patients with a metastatic colorectal cancer (mCRC) or gastrointestinal stromal tumour (GIST).

To determine the influence of esomeprazole on the AUC of regorafenib in patients with mCRC or GIST.

POLYP DETECTION WITH THE PEERSCOPE SYSTEM*: A RANDOMIZED TANDEM COLONOSCOPY STUDY

To compare the additional diagnostic yield obtained by using the PeerScope System* extended view vs. the diagnostic yield obtained by the Standard view colonoscopy.In addition, time measurements including time to cecum, time for withdrawal and…

Evaluation of a Second Generation High Definition and Narrow Band Imaging System for the Detection and Characterization of Colorectal Adenomas (EXERA III Colorectal Adenoma Study)

Evaluation of the effectiveness of a new system HD2/NBI2 to improve the detection of colorectal neoplastic lesions during colonoscopy in comparison to the former generation with currently highest share of the installed base (nonHD-nonNBI system i.e…

An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU 285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

Primary Objective:* The primary objective is to demonstrate the efficacy of avapritinib based on progression-free survival (PFS) determined by central radiological assessment per modified Response Evaluation Criteria in Solid Tumors (mRECIST),…

A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)

Primary Objective & HypothesisIn subjects with first line (1L) stage IV MSI-H or dMMR CRC treated with first line (1L) pembrolizumab (MK-3475) versus SOC chemotherapies,Objective: To compare Progression Free Survival (PFS) per RECIST 1.1 by…